Purpose The aim of this study was to evaluate the cost-effectiveness of nivolumab versus
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …

Objectives To evaluate the cost-effectiveness, from an Australian health system perspective,
of nivolumab versus ipilimumab for treatment of patients with previously-untreated, BRAF …

Objectives To assess the cost-effectiveness of pembrolizumab to treat unresectable or
metastatic melanoma in patients progressing after treatment with ipilimumab, and if …

The combination of ipilimumab and nivolumab is a highly active systemic therapy for
metastatic melanoma but can cause significant toxicity. We explore the safety and efficacy of …

Background Results from phase 2 and 3 trials in patients with advanced melanoma have
shown significant improvements in the proportion of patients achieving an objective …

PURPOSE The CheckMate 066 trial investigated nivolumab monotherapy as first-line
treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five …

Aim To show whether either nivolumab in combination with ipilimumab or nivolumab
monotherapy vs. ipilimumab monotherapy extends overall survival (OS) or progression‐free …

Importance This analysis provides long-term follow-up in patients withBRAFwild-type
advanced melanoma receiving first-line therapy based on anti–programmed cell death 1 …

Aim: To compare effectiveness of nivolumab+ ipilimumab (NIVO+ IPI) versus BRAF+ MEK
inhibitors (BRAFi+ MEKi) in patients with BRAF-mutant advanced melanoma in the real …

Immune checkpoint and MAP kinase pathway inhibitors can significantly improve long-term
survival for patients with melanoma. There is limited real-world data of these regimens' …